Inovio Pharmaceuticals, Inc.
INONext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for INO. That does not mean none is planned.
Get an email about INO's next catalysts
Track Inovio Pharmaceuticals (INO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 2 past
INO Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.20 | FQ end Sep/2026 | Call: amc
How INO's past catalysts played out
Market Overview
Stock performance and key metrics
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development (June 2020).
WebsiteVGX-3100
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)
INO-4700
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
VGX 3100
Cervical Intraepithelial Neoplasia
INO-5401
Glioblastoma
INO-3112
Head and Neck Squamous Cell Cancer
INO-9012
Urothelial Carcinoma
GLS-5300
Healthy
p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine
Leukaemia (Acute)
INO-4800
Coronavirus Infection
HPV DNA Plasmids Therapeutic Vaccine VGX-3100
Anal Intraepithelial Neoplasia
INO-3107
Respiratory Papillomatosis
INO-6145
HIV-1-infection
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
VGX-3100 | Phase 3 | Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) | - | - |
INO-4700 | Phase 2 | Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | - | - |
VGX 3100 | Phase 2 | Cervical Intraepithelial Neoplasia | - | - |
INO-5401 | Phase 2 | Glioblastoma | - | - |
INO-3112 | Phase 2 | Head and Neck Squamous Cell Cancer | - | - |
INO-9012 | Phase 2 | Urothelial Carcinoma | - | - |
GLS-5300 | Phase 2 | Healthy | - | - |
p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine | Phase 2 | Leukaemia (Acute) | - | - |
INO-4800 | Phase 2 | Coronavirus Infection | - | - |
HPV DNA Plasmids Therapeutic Vaccine VGX-3100 | Phase 2 | Anal Intraepithelial Neoplasia | - | - |
INO-3107 | Phase 2 | Respiratory Papillomatosis | - | - |
INO-6145 | Phase 2 | HIV-1-infection | - | - |
Recurrent Respiratory Papillomatosis
1 drug in this indication
Reduce the frequency of surgery in adults with Recurrent Respiratory Papillomatosis (RRP)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Inovio Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 12 drug candidates in Inovio Pharmaceuticals, Inc.'s (INO) pipeline across Phase 3, Phase 2. Its lead program is VGX-3100 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Inovio Pharmaceuticals, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Inovio Pharmaceuticals, Inc. (INO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track INO biotech catalysts?→
Add INO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Inovio Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.